已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

MM-087 Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome With REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase 1/2 First-In-Human Study in Patients With Relapsed/Refractory Multiple Myeloma

医学 耐受性 内科学 养生 细胞因子释放综合征 耐火材料(行星科学) 来那度胺 中性粒细胞减少症 多发性骨髓瘤 不利影响 肿瘤科 外科 毒性 免疫疗法 嵌合抗原受体 癌症 物理 天体生物学
作者
Jeffrey A. Zonder,Joshua Richter,Naresh Bumma,Jason Brayer,James E. Hoffman,William Bensinger,Ka Lung Wu,Linzhi Xu,Dhruti Chokshi,Anita Boyapati,Damien M. Cronier,Yariv Houvras,Karen Rodriguez Lorenc,Glenn S. Kroog,Madhav V. Dhodapkar,Suzanne Lentzsch,Dennis Cooper,Sundar Jagannath
出处
期刊:Clinical Lymphoma, Myeloma & Leukemia [Elsevier BV]
卷期号:22: S406-S407 被引量:3
标识
DOI:10.1016/s2152-2650(22)01591-9
摘要

Despite advances in treatment options, multiple myeloma remains incurable. REGN5458 is a BCMAxCD3 bispecific antibody under investigation in relapsed/refractory multiple myeloma (RRMM): ongoing Phase 1/2 trial (NCT03761108).To describe updated safety, overall response, and response durability in patients treated with REGN5458 in the Phase 1 part.The Phase 1 part follows a modified 3+3 dose-escalation design (4+3).Eligible patients with progressive RRMM, who were double- or triple-refractory, or intolerant to prior lines of systemic therapy, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 antibody, were included.Sixteen weekly infusions of REGN5458 monotherapy, then every two weeks until disease progression.Primary objectives were to assess safety, tolerability, and occurrence of dose-limiting toxicities of REGN5458, and to determine a recommended Phase 2 dose regimen. The objective response rate by modified International Myeloma Working Group criteria was a key secondary objective.At data cut-off (September 30, 2021), 73 patients were treated with REGN5458 in the dose-escalation cohort, with full doses ranging from 3-800 mg. The median age at enrollment was 64 years (range, 41-81). As per the Revised International Staging System, stages were 1, 2, or 3 in 15.0%, 57.5%, and 23.3% of patients, respectively. Patients had a median of five prior lines of systemic therapy (range, 2-17), with 89% of patients being triple-refractory. The median duration of follow-up was 3.0 months (range, 0.7-22.1). The most common treatment-emergent adverse events (TEAEs) were fatigue (45.2%), cytokine release syndrome (CRS) (38.4%), pyrexia (35.6%), and nausea (32.9%). There were no Grade ≥3 CRS or Grade ≥3 neurotoxicity events, and no treatment discontinuation due to CRS. Grade 3 and 4 TEAEs were reported in 31 (42.5%) and 24 patients (32.9%), respectively. The most common Grade 3/4 TEAEs were hematologic (39.0%). Responses were observed at all dose levels. Amongst patients treated at the 200-800 mg dose levels, the response rate was 75% (n=18/24). The median duration of response was not reached.REGN5458 shows early, deep, and durable responses with a manageable safety profile in triple or greater-refractory patients with RRMM. This study is funded by Regeneron.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
3秒前
大神水瓶座完成签到,获得积分10
4秒前
yamo完成签到 ,获得积分10
5秒前
万能图书馆应助刘光正采纳,获得10
5秒前
5秒前
5秒前
七慕凉应助魏芸芸采纳,获得10
6秒前
默笙完成签到 ,获得积分10
7秒前
qsq完成签到 ,获得积分10
7秒前
8秒前
9秒前
9秒前
繁笙完成签到 ,获得积分10
10秒前
田鹤飞发布了新的文献求助10
11秒前
11秒前
小星星发布了新的文献求助10
13秒前
22222发布了新的文献求助10
14秒前
聂难敌发布了新的文献求助10
15秒前
苏姗姗发布了新的文献求助10
16秒前
guozizi发布了新的文献求助30
16秒前
18秒前
吃鲨鱼的小虾米完成签到 ,获得积分10
18秒前
徐凤年完成签到,获得积分10
20秒前
20秒前
执着的采枫完成签到 ,获得积分10
21秒前
闲得追月时完成签到,获得积分10
22秒前
23秒前
大恶魔宝拉完成签到,获得积分20
23秒前
聂难敌完成签到,获得积分10
23秒前
24秒前
24秒前
Denmark完成签到 ,获得积分10
24秒前
anan完成签到 ,获得积分10
24秒前
25秒前
TXZ06完成签到,获得积分10
25秒前
英姑应助典雅的纸飞机采纳,获得10
27秒前
27秒前
28秒前
李健应助科研通管家采纳,获得10
28秒前
28秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976560
求助须知:如何正确求助?哪些是违规求助? 3520659
关于积分的说明 11204287
捐赠科研通 3257271
什么是DOI,文献DOI怎么找? 1798653
邀请新用户注册赠送积分活动 877835
科研通“疑难数据库(出版商)”最低求助积分说明 806570